Multi-system disorders of glycosphingolipid and ganglioside metabolism

Journal of Lipid Research

Volumn 51, Issue 7, 2010, Pages 1643-1675

  Xu, You Hai ^a   Barnes, Sonya ^a   Sun, Ying ^a   Grabowski, Gregory A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Brain development; Lysosomal storage diseases; Neuronal degeneration; Pathological mechanism

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; AMBROXOL; AMIGAL; CERAMIDE; ENZYME; EXR 101; EXR 202; GANGLIOSIDE; GENZ 112368; GLYCOSPHINGOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IBUPROFEN; IMIGLUCERASE; INDOMETACIN; MIGLUSTAT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PLICERA; PROSAPOSIN; PYRIMETHAMINE; RAS PROTEIN; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELAGLUCERASE;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DEVELOPMENTAL STAGE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME REPLACEMENT; FABRY DISEASE; FARBER DISEASE; GAUCHER DISEASE; GENE MUTATION; GLOBOID CELL LEUKODYSTROPHY; GM1 GANGLIOSIDOSIS; HUMAN; INFLAMMATION; LIPID DEGRADATION; LIPID METABOLISM; LIPIDOSIS; LIPOGENESIS; LYSOSOME STORAGE DISEASE; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SANDHOFF DISEASE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TAY SACHS DISEASE; ANIMAL; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHEMISTRY; DEGENERATIVE DISEASE; LYSOSOMAL STORAGE DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; HUMANS; INFLAMMATION; LYSOSOMAL STORAGE DISEASES; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES;

EID: 77953499076     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R003996     Document Type: Review

References (378)

1. Holthuis, J. C., T. Pomorski, R. J. Raggers, H. Sprong, and G. Van Meer. 2001. The organizing potential of sphingolipids in intracellular membrane transport. Physiol. Rev. 81: 1689-1723. (Pubitemid 32947781)
2. Kolter, T., and K. Sandhoff. 2005. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 21: 81-103.
3. Lahiri, S., and A. H. Futerman. 2007. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64: 2270-2284.
4. Mandon, E. C., I. Ehses, J. Rother, G. van Echten, and K. Sandhoff. 1992. Subcellular localization and membrane topology of serine pal mitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver. J. Biol. Chem. 267: 11144-11148.
5. Michel, C., G. van Echten-Deckert, J. Rother, K. Sandhoff, E. Wang, and A. H. Merrill, Jr. 1997. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-transdouble bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. 272: 22432-22437.
6. Pruett, S. T., A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill, Jr. 2008. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J. Lipid Res. 49: 1621-1639.
7. Rosenthal, M. D. 1987. Fatty acid metabolism of isolated mammalian cells. Prog. Lipid Res. 26: 87-124.
8. Rother, J., G. van Echten, G. Schwarzmann, and K. Sandhoff. 1992. Biosynthesis of sphingolipids: dihydroceramide and not sphinganine is desaturated by cultured cells. Biochem. Biophys. Res. Commun. 189: 14-20.
9. Pewzner-Jung, Y., S. Ben-Dor, and A. H. Futerman. 2006. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J. Biol. Chem. 281: 25001-25005.
10. Jenkins, R. W., D. Canals, and Y. A. Hannun. 2009. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell. Signal. 21: 836-846.
11. Marchesini, N., and Y. A. Hannun. 2004. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem. Cell Biol. 82: 27-44.
12. Kitatani, K., K. Sheldon, V. Rajagopalan, V. Anelli, R. W. Jenkins, Y. Sun, G. A. Grabowski, L. M. Obeid, and Y. A. Hannun. 2009. Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J. Biol. Chem. 284: 12972-12978.
13. Burkart, T., H. P. Siegrist, N. N. Herschkowitz, and U. N. Wiesmann. 1977. 3 ? -phosphoadenylylsulfate:galactosylceramide 3 ? -sulfotransferase. An optimized assay in homogenates of developing brain. Biochim. Biophys. Acta. 483: 303-311. (Pubitemid 8155881)
14. Yaghootfam, A., T. Sorkalla, H. Haberlein, V. Gieselmann, J. Kappler, and M. Eckhardt. 2007. Cerebroside sulfotransferase forms homodimers in living cells. Biochemistry. 46: 9260-9269.
15. Futerman, A. H., B. Stieger, A. L. Hubbard, and R. E. Pagano. 1990. Sphingomyelin synthesis in rat liver occurs predominantly at the cis and medial cisternae of the Golgi apparatus. J. Biol. Chem. 265: 8650-8657. (Pubitemid 20167377)
16. Hanada, K., K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, and M. Nishijima. 2003. Molecular machinery for nonvesicular trafficking of ceramide. Nature. 426: 803-809.
17. Lannert, H., C. Bunning, D. Jeckel, and F. T. Wieland. 1994. Lactosylceramide is synthesized in the lumen of the Golgi apparatus. FEBS Lett. 342: 91-96.
18. Lloyd, K. O., and K. Furukawa. 1998. Biosynthesis and functions of gangliosides: recent advances. Glycoconj. J. 15: 627-636.
19. Iwamori, M., J. Shimomura, S. Tsuyuhara, and Y. Nagai. 1984. Gangliosides of various rat tissues: distribution of ganglio-N-tetraose-containing gangliosides and tissue-characteristic composition of gangliosides. J Biochem. 95: 761-770. (Pubitemid 14130537)
20. Freischutz, B., M. Saito, H. Rahmann, and R. K. Yu. 1994. Activities of five different sialyltransferases in fish and rat brains. J. Neurochem. 62: 1965-1973.
21. Senn, H. J., C. Manke, P. Dieter, T. A. Tran-Thi, E. Fitzke, W. Gerok, and K. Decker. 1990. Ganglioside biosynthesis in rat liver: different distribution of ganglioside synthases in hepatocytes, Kupffer cells, and sinusoidal endothelial cells. Arch. Biochem. Biophys. 278: 161-167.
22. Yu, R. K., Y. Nakatani, and M. Yanagisawa. 2009. The role of glycosphingolipid metabolism in the developing brain. J. Lipid Res. 50 ( Suppl. ): S440-S445.
23. Eckford, P. D., and F. J. Sharom. 2005. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389: 517-526.
24. De Rosa, M. F., D. Sillence, C. Ackerley, and C. Lingwood. 2004. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279: 7867-7876.
25. van Helvoort, A., A. J. Smith, H. Sprong, I. Fritzsche, A. H. Schinkel, P. Borst, and G. van Meer. 1996. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 87: 507-517.
26. Halter, D., S. Neumann, S. M. van Dijk, J. Wolthoorn, A. M. de Maziere, O. V. Vieira, P. Mattjus, J. Klumperman, G. van Meer, and H. Sprong. 2007. Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell Biol. 179: 101-115.
27. D'Angelo, G., E. Polishchuk, G. Di Tullio, M. Santoro, A. Di Campli, A. Godi, G. West, J. Bielawski, C. C. Chuang, A. C. van der Spoel, et al. 2007. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature. 449: 62-67.
28. Brown, R. E., and P. Mattjus. 2007. Glycolipid transfer proteins. Biochim. Biophys. Acta. 1771: 746-760.
29. Rorman, E. G., and G. A. Grabowski. 1989. Molecular cloning of a human co-beta-glucosidase cDNA: evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and rats. Genomics. 5: 486-492.
30. Hiraiwa, M., B. M. Martin, Y. Kishimoto, G. E. Conner, S. Tsuji, and J. S. O'Brien. 1997. Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch. Biochem. Biophys. 341: 17-24.
31. Leonova, T., X. Qi, A. Bencosme, E. Ponce, Y. Sun, and G. A. Grabowski. 1996. Proteolytic processing patterns of prosaposin in insect and mammalian cells. J. Biol. Chem. 271: 17312-17320.
32. Hannun, Y. A., C. Luberto, and K. M. Argraves. 2001. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry. 40: 4893-4903.
33. Degroote, S., J. Wolthoorn, and G. van Meer. 2004. The cell biology of glycosphingolipids. Semin. Cell Dev. Biol. 15: 375-387.
34. Memon, R. A., W. M. Holleran, Y. Uchida, A. H. Moser, S. Ichikawa, Y. Hirabayashi, C. Grunfeld, and K. R. Feingold. 1999. Regulation of glycosphingolipid metabolism in liver during the acute phase response. J. Biol. Chem. 274: 19707-19713.
35. Bourteele, S., A. Hausser, H. Doppler, J. Horn-Muller, C. Ropke, G. Schwarzmann, K. Pfizenmaier, and G. Muller. 1998. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J. Biol. Chem. 273: 31245-31251.
36. Huwiler, A., T. Kolter, J. Pfeilschifter, and K. Sandhoff. 2000. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta. 1485: 63-99.
37. Tettamanti, G., R. Bassi, P. Viani, and L. Riboni. 2003. Salvage pathways in glycosphingolipid metabolism. Biochimie. 85: 423-437.
38. Walkley, S. U., and M. T. Vanier. 2009. Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta. 1793: 726-736.
39. Eliyahu, E., J. H. Park, N. Shtraizent, X. He, and E. H. Schuchman. 2007. Acid ceramidase is a novel factor required for early embryo survival. FASEB J. 21: 1403-1409.
40. Hakomori, S. I. 2000. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj. J. 17: 143-151.
41. Fenderson, B. A., P. W. Andrews, E. Nudelman, H. Clausen, and S. Hakomori. 1987. Glycolipid core structure switching from globo - to lacto- and ganglio-series during retinoic acid-induced differentiation of TERA-2-derived human embryonal carcinoma cells. Dev. Biol. 122: 21-34.
42. Kannagi, R., S. B. Levery, F. Ishigami, S. Hakomori, L. H. Shevinsky, B. B. Knowles, and D. Solter. 1983. New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J. Biol. Chem. 258: 8934-8942. (Pubitemid 13026724)
43. Ngamukote, S., M. Yanagisawa, T. Ariga, S. Ando, and R. K. Yu. 2007. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem. 103: 2327-2341
44. Seyfried, T. N., and T. Ariga. 1992. Neutral glycolipid abnormalities in a t-complex mutant mouse embryo. Biochem. Genet. 30: 557-565.
45. van der Pal, R. H., W. Klein, L. M. van Golde, and M. Lopes- Cardozo. 1990. Galactosylceramide sulfotransferase, arylsulfatase A and cerebroside sulfatase activity in different regions of developing rat brain. Biochim. Biophys. Acta. 1043: 91-96.
46. Ishii, A., T. Ikeda, S. Hitoshi, I. Fujimoto, T. Torii, K. Sakuma, S. Nakakita, S. Hase, and K. Ikenaka. 2007. Developmental changes in the expression of glycogenes and the content of N-glycans in the mouse cerebral cortex. Glycobiology. 17: 261-276.
47. Yamamoto, A., M. Haraguchi, S. Yamashiro, S. Fukumoto, K. Furukawa, K. Takamiya, M. Atsuta, and H. Shiku. 1996. Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development. J. Neurochem. 66: 26-34.
48. Yu, R. K., L. J. Macala, T. Taki, H. M. Weinfield, and F. S. Yu. 1988. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J. Neurochem. 50: 1825-1829.
49. Hojjati, M. R., Z. Li, and X. C. Jiang. 2005. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim. Biophys. Acta. 1737: 44-51.
50. Yamashita, T., R. Wada, T. Sasaki, C. Deng, U. Bierfreund, K. Sandhoff, and R. L. Proia. 1999. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. USA. 96: 9142-9147.
51. Bosio, A., E. Binczek, and W. Stoffel. 1996. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc. Natl. Acad. Sci. USA. 93: 13280-13285.
52. Coetzee, T., N. Fujita, J. Dupree, R. Shi, A. Blight, K. Suzuki, and B. Popko. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 86: 209-219.
53. Yoshikawa, M., S. Go, K. Takasaki, Y. Kakazu, M. Ohashi, M. Nagafuku, K. Kabayama, J. Sekimoto, S. Suzuki, K. Takaiwa, et al. 2009. Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti. Proc. Natl. Acad. Sci. USA. 106: 9483-9488.
54. Yamashita, T., A. Hashiramoto, M. Haluzik, H. Mizukami, S. Beck, A. Norton, M. Kono, S. Tsuji, J. L. Daniotti, N. Werth, et al. 2003. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA. 100: 3445-3449.
55. Takamiya, K., A. Yamamoto, K. Furukawa, S. Yamashiro, M. Shin, M. Okada, S. Fukumoto, M. Haraguchi, N. Takeda, K. Fujimura, et al. 1996. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc. Natl. Acad. Sci. USA. 93: 10662-10667.
56. Handa, Y., N. Ozaki, T. Honda, K. Furukawa, Y. Tomita, M. Inoue, K. Furukawa, M. Okada, and Y. Sugiura. 2005. GD3 synthase gene knockout mice exhibit thermal hyperalgesia and mechanical allodynia but decreased response to formalin-induced prolonged noxious stimulation. Pain. 117: 271-279.
57. Saadat, L., J. L. Dupree, J. Kilkus, X. Han, M. Traka, R. L. Proia, G. Dawson, and B. Popko. 2010. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia. 58: 391-398.
58. Jennemann, R., R. Sandhoff, S. Wang, E. Kiss, N. Gretz, C. Zuliani, A. Martin-Villalba, R. Jager, H. Schorle, M. Kenzelmann, et al. 2005. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc. Natl. Acad. Sci. USA. 102: 12459-12464.
59. Auer-Grumbach, M. 2008. Hereditary sensory neuropathy type I. Orphanet J. Rare Dis. 3: 7.
60. Dawkins, J. L., D. J. Hulme, S. B. Brahmbhatt, M. Auer-Grumbach, and G. A. Nicholson. 2001. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat. Genet. 27: 309-312.
61. Fishman, P. H., S. R. Max, J. F. Tallman, R. O. Brady, N. K. Maclaren, and M. Cornblath. 1975. Deficient Ganglioside Biosynthesis: a novel human sphingolipidosis. Science. 187: 68-70.
62. Penno, A., M. M. Reilly, H. Houlden, M. Laura, K. Rentsch, V. Niederkofler, E. T. Stoeckli, G. Nicholson, F. Eichler, R. H. Brown, Jr., A. von Eckardstein, and T. Hornemann. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem. Epub 2010 Jan 21.
63. Rotthier, A., J. Baets, E. De Vriendt, A. Jacobs, M. Auer- Grumbach, N. Levy, N. Bonello-Palot, S. S. Kilic, J. Weis, A. Nascimento, et al. 2009. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain. 132: 2699-2711.
64. Simpson, M. A., H. Cross, C. Proukakis, D. A. Priestman, D. C. Neville, G. Reinkensmeier, H. Wang, M. Wiznitzer, K. Gurtz, A. Verganelaki, et al. 2004. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 36: 1225-1229.
65. Matyas, G. R., and D. J. Morre. 1987. Subcellular distribution and biosynthesis of rat liver gangliosides. Biochim. Biophys. Acta. 921: 599-614.
66. Baek, R. C., D. R. Martin, N. R. Cox, and T. N. Seyfried. 2009. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids. 44: 197-205.
67. Kawashima, I., I. Nagata, and T. Tai. 1996. Immunocytochemical analysis of gangliosides in rat primary cerebellar cultures using specific monoclonal antibodies. Brain Res. 732: 75-86.
68. Jirkovska, M., F. Majer, J. Smidova, J. Stritesky, G. M. Shaik, P. Draber, L. Vitek, Z. Marecek, and F. Smid. 2007. Changes in GM1 ganglioside content and localization in cholestatic rat liver. Glycoconj. J. 24: 231-241.
69. Muthing, J., U. Maurer, U. Neumann, B. Kniep, and S. Weber-Schurholz. 1998. Glycosphingolipids of skeletal muscle: I. Subcellular distribution of neutral glycosphingolipids and gangliosides in rabbit skeletal muscle. Carbohydr. Res. 307: 135-145.
70. Muthing, J., U. Maurer, K. Sostaric, U. Neumann, H. Brandt, S. Duvar, J. Peter-Katalinic, and S. Weber-Schurholz. 1994. Different distributions of glycosphingolipids in mouse and rabbit skeletal muscle demonstrated by biochemical and immunohistological analyses. J Biochem. 115: 248-256.
71. Schaeren-Wiemers, N., P. van der Bijl, and M. E. Schwab. 1995. The UDP-galactose:ceramide galactosyltransferase: expression pattern in oligodendrocytes and Schwann cells during myelination and substrate preference for hydroxyceramide. J. Neurochem. 65: 2267-2278.
72. Feingold, K. R. 2007. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 48: 2531-2546.
73. van Genderen, I. L., G. van Meer, J. W. Slot, H. J. Geuze, and W. F. Voorhout. 1991. Subcellular localization of Forssman glycolipid in epithelial MDCK cells by immuno-electronmicroscopy after freeze-substitution. J. Cell Biol. 115: 1009-1019.
74. Dyatlovitskaya, E. V., A. M. Novikov, N. P. Gorkova, and L. D. Bergelson. 1976. Gangliosides of hepatoma 27, normal and regenerating rat liver. Eur. J. Biochem. 63: 357-364.
75. Malisan, F., and R. Testi. 2002. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta. 1585: 179-187.
76. Simons, K., and G. van Meer. 1988. Lipid sorting in epithelial cells. Biochemistry. 27: 6197-6202.
77. Sprong, H., S. Degroote, T. Claessens, J. van Drunen, V. Oorschot, B. H. Westerink, Y. Hirabayashi, J. Klumperman, P. van der Sluijs, and G. van Meer. 2001. Glycosphingolipids are required for sorting melanosomal proteins in the Golgi complex. J. Cell Biol. 155: 369-380.
78. Brasitus, T. A., and D. Schachter. 1980. Lipid dynamics and lipid-protein interactions in rat enterocyte basolateral and microvillus membranes. Biochemistry. 19: 2763-2769.
79. Forstner, G. G., K. Tanaka, and K. J. Isselbacher. 1968. Lipid composition of the isolated rat intestinal microvillus membrane. Biochem. J. 109: 51-59.
80. Warnock, D. E., C. Roberts, M. S. Lutz, W. A. Blackburn, W. W. Young, Jr., and J. U. Baenziger. 1993. Determination of plasma membrane lipid mass and composition in cultured Chinese hamster ovary cells using high gradient magnetic affinity chromatography. J. Biol. Chem. 268: 10145-10153.
81. Buton, X., P. Herve, J. Kubelt, A. Tannert, K. N. Burger, P. Fellmann, P. Muller, A. Herrmann, M. Seigneuret, and P. F. Devaux. 2002. Transbilayer movement of monohexosylsphingolipids in endoplasmic reticulum and Golgi membranes. Biochemistry. 41: 13106-13115.
82. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1: 31-39.
83. Rodgers, W., B. Crise, and J. K. Rose. 1994. Signals determining protein tyrosine kinase and glycosyl-phosphatidylinositolanchored protein targeting to a glycolipid-enriched membrane fraction. Mol. Cell. Biol. 14: 5384-5391. (Pubitemid 24235966)
84. Hakomori, S., and K. Handa. 2002. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 531: 88-92.
85. Hakomori, S. 2003. Structure, organization, and function of glycosphingolipids in membrane. Curr. Opin. Hematol. 10: 16-24.
86. Patel, H. H., F. Murray, and P. A. Insel. 2008. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb. Exp. Pharmacol. 167-184.
87. Hannun, Y. A., and L. M. Obeid. 2002. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277: 25847-25850.
88. Brown, M. D., and D. B. Sacks. 2009. Protein scaffolds in MAP kinase signalling. Cell. Signal. 21: 462-469.
89. Muller, G., M. Ayoub, P. Storz, J. Rennecke, D. Fabbro, and K. Pfizenmaier. 1995. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14: 1961-1969.
90. Zhang, Y., B. Yao, S. Delikat, S. Bayoumy, X. H. Lin, S. Basu, M. McGinley, P. Y. Chan-Hui, H. Lichenstein, and R. Kolesnick. 1997. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell. 89: 63-72.
91. Verheij, M., R. Bose, X. H. Lin, B. Yao, W. D. Jarvis, S. Grant, M. J. Birrer, E. Szabo, L. I. Zon, J. M. Kyriakis, et al. 1996. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 380: 75-79.
92. Huwiler, A., J. Brunner, R. Hummel, M. Vervoordeldonk, S. Stabel, H. van den Bosch, and J. Pfeilschifter. 1996. Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc. Natl. Acad. Sci. USA. 93: 6959-6963. (Pubitemid 26243482)
93. Ruvolo, P. P., W. Clark, M. Mumby, F. Gao, and W. S. May. 2002. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J. Biol. Chem. 277: 22847-22852.
94. Leinekugel, P., S. Michel, E. Conzelmann, and K. Sandhoff. 1992. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum. Genet. 88: 513-523.
95. Grabowski, G. A., E. H. Kolodny, N. J. Weinreb, B. E. Rosenbloom, A. Prakash-Cheng, P. Kaplan, J. Charrow, G. M. Pastores, and P. K. Mistry. 2006. Gaucher disease: phenotypic and genetic variation. Chapter 146.1. In The Metabolic and Molecular Bases of Inherited Diseases. C. R. Scriver, W. S. Sly, A. Beaudet, D. Valle, and B. Childs, editors. McGraw-Hill, New York.
96. Moser, H., T. Linke, A. H. Fensom, T. Levade, and K. Sandhoff. 2001. Acid ceramidase deficiency: Farber lipogranulomatosis. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3573-3588.
97. Sugita, M., J. T. Dulaney, and H. W. Moser. 1972. Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science. 178: 1100-1102.
98. Matsuda, J., M. Kido, K. Tadano-Aritomi, I. Ishizuka, K. Tominaga, K. Toida, E. Takeda, K. Suzuki, and Y. Kuroda. 2004. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse. Hum. Mol. Genet. 13: 2709-2723.
99. Gatt, S. 1963. Enzymic hydrolysis and synthesis of ceramides. J. Biol. Chem. 238: 3131-3133.
100. Okino, N., X. He, S. Gatt, K. Sandhoff, M. Ito, and E. H. Schuchman. 2003. The reverse activity of human acid ceramidase. J. Biol. Chem. 278: 29948-29953.
101. Ehlert, K., M. Frosch, N. Fehse, A. Zander, J. Roth, and J. Vormoor. 2007. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr. Rheumatol. Online J. 5: 15.
102. Li, C. M., J. H. Park, C. M. Simonaro, X. He, R. E. Gordon, A. H. Friedman, D. Ehleiter, F. Paris, K. Manova, S. Hepbildikler, et al. 2002. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics. 79: 218-224.
103. Cutler, R. G., and M. P. Mattson. 2001. Sphingomyelin and ceramide as regulators of development and lifespan. Mech. Ageing Dev. 122: 895-908.
104. Schuchman, E. H., and R. J. Desnick. 2001. Niemann-Pick Disease Types A and B: acid sphingomyelinase deficencies. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A.L. Beaudet, W.S. Sly, and Valle, D., editor. McGraw-Hill. 3589-3610.
105. Horinouchi, K., S. Erlich, D. P. Perl, K. Ferlinz, C. L. Bisgaier, K. Sandhoff, R. J. Desnick, C. L. Stewart, and E. H. Schuchman. 1995. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 10: 288-293.
106. Otterbach, B., and W. Stoffel. 1995. Acid sphingomyelinasedefi cient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell. 81: 1053-1061.
107. Hostetler, K. Y., and P. J. Yazaki. 1979. The subcellular localization of neutral sphingomyelinase in rat liver. J. Lipid Res. 20: 456-463. (Pubitemid 9215373)
108. Li, C. M., J. H. Park, X. He, B. Levy, F. Chen, K. Arai, D. A. Adler, C. M. Disteche, J. Koch, K. Sandhoff, et al. 1999. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics. 62: 223-231.
109. Schuchman, E. H. 2007. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J. Inherit. Metab. Dis. 30: 654-663.
110. Kobayashi, T., N. Shinnoh, I. Goto, and Y. Kuroiwa. 1985. Hydrolysis of galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases. J. Biol. Chem. 260: 14982-14987. (Pubitemid 16188361)
111. Wenger, D., K. Suzuki, Y. Suzuki, and K. Suzuki. 2001. Galactosylceramide lipodosis: globoid cell leukodystrophy (Krabbe disease). In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3669-3694.
112. Suzuki, A., and K. Furukawa. 2003. [Glycobiology basics: glycolipids]. Tanpakushitsu Kakusan Koso. 48: 923-928.
113. Wenger, D. A., M. A. Rafi, P. Luzi, J. Datto, and E. Costantino- Ceccarini. 2000. Krabbe disease: genetic aspects and progress toward therapy. Mol. Genet. Metab. 70: 1-9.
114. Duffner, P. K., V. S. Caviness, Jr., R. W. Erbe, M. C. Patterson, K. R. Schultz, D. A. Wenger, and C. Whitley. 2009. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet. Med. 11: 450-454.
115. Sakai, N., K. Inui, N. Tatsumi, H. Fukushima, T. Nishigaki, M. Taniike, J. Nishimoto, H. Tsukamoto, I. Yanagihara, K. Ozono, et al. 1996. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J. Neurochem. 66: 1118-1124.
116. Kobayashi, T., T. Yamanaka, J. M. Jacobs, F. Teixeira, and K. Suzuki. 1980. The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res. 202: 479-483.
117. Suzuki, K., and K. Suzuki. 1995. The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol. 5: 249-258.
118. Suzuki, K., and M. Taniike. 1995. Murine model of genetic demyelinating disease: the twitcher mouse. Microsc. Res. Tech. 32: 204-214.
119. Taniike, M., and K. Suzuki. 1994. Spacio-temporal progression of demyelination in twitcher mouse: with clinico-pathological correlation. Acta Neuropathol. 88: 228-236.
120. Luzi, P., M. A. Rafi, M. Zaka, M. Curtis, M. T. Vanier, and D. A. Wenger. 2001. Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease). Mol. Genet. Metab. 73: 211-223.
121. Hoogerbrugge, P. M., K. Suzuki, B. J. Poorthuis, T. Kobayashi, G. Wagemaker, and D. W. van Bekkum. 1988. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science. 239: 1035-1038.
122. Figura, K., V. Gieselmann, and J. Jaeken. 2001. Metachromatic leukodystrophy. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3695-3724.
123. Wolfe, H. J., and G. G. Pietra. 1964. The visceral lesions of metachromatic leukodystrophy. Am. J. Pathol. 44: 921-930.
124. Sandhoff, K., T. Kolter, and K. Harzer. 2001. Sphingolipid activator proteins. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3371-3388.
125. Dierks, T., L. Schlotawa, M. A. Frese, K. Radhakrishnan, K. von Figura, and B. Schmidt. 2009. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease: lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim. Biophys. Acta. 1793: 710-725.
126. Cosma, M. P., S. Pepe, I. Annunziata, R. F. Newbold, M. Grompe, G. Parenti, and A. Ballabio. 2003. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 113: 445-456.
127. Schlotawa, L., R. Steinfeld, K. von Figura, T. Dierks, and J. Gartner. 2008. Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. Hum. Mutat. 29: 205.
128. Biffi, A., G. Lucchini, A. Rovelli, and M. Sessa. 2008. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant. 42 ( Suppl. 2 ): S2-S6.
129. Hess, B., P. Saftig, D. Hartmann, R. Coenen, R. Lullmann-Rauch, H. H. Goebel, M. Evers, K. von Figura, R. D'Hooge, G. Nagels, et al. 1996. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Natl. Acad. Sci. USA. 93: 14821-14826.
130. Ramakrishnan, H., K. K. Hedayati, R. Lullmann-Rauch, C. Wessig, S. N. Fewou, H. Maier, H. H. Goebel, V. Gieselmann, and M. Eckhardt. 2007. Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J. Neurosci. 27: 9482-9490.
131. Matzner, U., and V. Gieselmann. 2005. Gene therapy of metachromatic leukodystrophy. Expert Opin. Biol. Ther. 5: 55-65.
132. Matzner, U., R. Lullmann-Rauch, S. Stroobants, C. Andersson, C. Weigelt, C. Eistrup, J. Fogh, R. D'Hooge, and V. Gieselmann. 2009. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 17: 600-606.
133. Brady, R. O., A. E. Gal, R. M. Bradley, E. Martensson, A. L. Warshaw, and L. Laster. 1967. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276: 1163-1167.
134. Desnick, R. J., R. Brady, J. Barranger, A. J. Collins, D. P. Germain, M. Goldman, G. Grabowski, S. Packman, and W. R. Wilcox. 2003. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138: 338-346.
135. Nance, C. S., C. J. Klein, M. Banikazemi, S. H. Dikman, R. G. Phelps, J. C. McArthur, M. Rodriguez, and R. J. Desnick. 2006. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch. Neurol. 63: 453-457.
136. Elleder, M. 2003. Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Acta Paediatr. Suppl. 92: 46-53, discussion 45. (Pubitemid 38134751)
137. Aerts, J. M., J. E. Groener, S. Kuiper, W. E. Donker-Koopman, A. Strijland, R. Ottenhoff, C. van Roomen, M. Mirzaian, F. A. Wijburg, G. E. Linthorst, et al. 2008. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA. 105: 2812-2817.
138. Rodrigues, L. G., M. J. Ferraz, D. Rodrigues, M. Pais-Vieira, D. Lima, R. O. Brady, M. M. Sousa, and M. C. Sa-Miranda. 2009. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol. Dis. 33: 48-56.
139. Park, J. L., S. E. Whitesall, L. G. D'Alecy, L. Shu, and J. A. Shayman. 2008. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin. Exp. Pharmacol. Physiol. 35: 1156-1163.
140. Shu, L., J. L. Park, J. Byun, S. Pennathur, J. Kollmeyer, and J. A. Shayman. 2009. Decreased nitric oxide bioavailability in a mouse model of fabry disease. J. Am. Soc. Nephrol. 20: 1975-1985.
141. Beutler, E., and G. A. Grabowski. 2001. Gaucher disease. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3635-3668.
142. Horowitz, M., S. Wilder, Z. Horowitz, O. Reiner, T. Gelbart, and E. Beutler. 1989. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 4: 87-96.
143. Walden, C. M., R. Sandhoff, C. C. Chuang, Y. Yildiz, T. D. Butters, R. A. Dwek, F. M. Platt, and A. C. van der Spoel. 2007. Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J. Biol. Chem. 282: 32655-32664.
144. Yildiz, Y., H. Matern, B. Thompson, J. C. Allegood, R. L. Warren, D. M. Ramirez, R. E. Hammer, F. K. Hamra, S. Matern, and D. W. Russell. 2006. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 116: 2985-2994.
145. Burrow, T. A., R. J. Hopkin, N. D. Leslie, B. T. Tinkle, and G. A. Grabowski. 2007. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 19: 628-635.
146. Elstein, D., A. Dweck, D. Attias, I. Hadas-Halpern, S. Zevin, G. Altarescu, J. F. Aerts, S. van Weely, and A. Zimran. 2007. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 110: 2296-2301.
147. Schiffmann, R., E. J. Fitzgibbon, C. Harris, C. DeVile, E. H. Davies, L. Abel, I. N. van Schaik, W. Benko, M. Timmons, M. Ries, et al. 2008. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann. Neurol. 64: 514-522.
148. Tybulewicz, V. L. J., M. L. Tremblay, M. E. LaMarca, R. Willemsen, B. K. Stubblefield, S. Winfield, B. Zablocka, E. Sidransky, B. M. Martin, S. P. Huang, et al. 1992. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature. 357: 407-410.
149. Enquist, I. B., C. Lo Bianco, A. Ooka, E. Nilsson, J. E. Mansson, M. Ehinger, J. Richter, R. O. Brady, D. Kirik, and S. Karlsson. 2007. Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA. 104: 17483-17488.
150. Xu, Y. H., R. Reboulet, B. Quinn, J. Huelsken, D. Witte, and G. A. Grabowski. 2008. Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels. Mol. Genet. Metab. 94: 190-203.
151. Suzuki, K. 1968. Cerebral GM1-gangliosidosis: chemical pathology of visceral organs. Science. 159: 1471-1472.
152. Hinek, A. 1996. Biological roles of the non-integrin elastin/laminin receptor. Biol. Chem. 377: 471-480.
153. Privitera, S., C. A. Prody, J. W. Callahan, and A. Hinek. 1998. The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J. Biol. Chem. 273: 6319-6326.
154. Callahan, J. W. 1999. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein. Biochim. Biophys. Acta. 1455: 85-103.
155. Suzuki, K., A. Oshima, and E. Nanba. 2001. β-Galactosidase Deficiency (β-Galactosidosis): GM1 gangliosidosis and Morquio B Disease. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3775-3809.
156. Hahn, C. N., M. del Pilar Martin, M. Schroder, M. T. Vanier, Y. Hara, K. Suzuki, and A. d'Azzo. 1997. Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum. Mol. Genet. 6: 205-211.
157. Matsuda, J., O. Suzuki, A. Oshima, A. Ogura, M. Naiki, and Y. Suzuki. 1997. Neurological manifestations of knockout mice with beta-galactosidase deficiency. Brain Dev. 19: 19-20.
158. Kasperzyk, J. L., A. d'Azzo, F. M. Platt, J. Alroy, and T. N. Seyfried. 2005. Substrate reduction reduces gangliosides in postnatal cerebrum- brainstem and cerebellum in GM1 gangliosidosis mice. J. Lipid Res. 46: 744-751.
159. Broekman, M. L., R. C. Baek, L. A. Comer, J. L. Fernandez, T. N. Seyfried, and M. Sena-Esteves. 2007. Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol. Ther. 15: 30-37.
160. Elliot-Smith, E., A. O. Speak, E. Lloyd-Evans, D. A. Smith, A. C. van der Spoel, M. Jeyakumar, T. D. Butters, R. A. Dwek, A. d'Azzo, and F. M. Platt. 2008. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol. Genet. Metab. 94: 204-211.
161. Gravel, R., M. M. Kaback, R. L. Proia, K. Sandhoff, K. Suzuki, and K. Suzuki. 2001. The GM2 gangliosidoses. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3827-3876.
162. Srivastava, S. K., and E. Beutler. 1973. Hexosaminidase-A and hexosaminidase-B: studies in Tay-Sachs' and Sandhoff's disease. Nature. 241: 463.
163. Proia, R. L., A. d'Azzo, and E. F. Neufeld. 1984. Association of alpha- and beta-subunits during the biosynthesis of beta-hexosaminidase in cultured human fibroblasts. J. Biol. Chem. 259: 3350-3354.
164. Sonderfeld-Fresko, S., and R. L. Proia. 1988. Synthesis and assembly of a catalytically active lysosomal enzyme, beta-hexosaminidase B, in a cell-free system. J. Biol. Chem. 263: 13463-13469.
165. Conzelmann, E., J. Burg, G. Stephan, and K. Sandhoff. 1982. Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2. Eur. J. Biochem. 123: 455-464.
166. Almassian, B. 2009. 4. Phase I trial of pyrimethamine to treat LOTS. Mol. Genet. Metab. 96: S12-S13.
167. Beutler, E., W. Kuhl, and D. Comings. 1975. Hexosaminidase isozyme in type O Gm2 gangliosidosis (Sandhoff-Jatzkewitz disease). Am. J. Hum. Genet. 27: 628-638.
168. Srivastava, S. K., and E. Beutler. 1974. Studies on human beta-D-N-acetylhexosaminidases. 3. Biochemical genetics of Tay-Sachs and Sandhoff's diseases. J. Biol. Chem. 249: 2054-2057.
169. Sango, K., S. Yamanaka, A. Hoffmann, Y. Okuda, A. Grinberg, H. Westphal, M. P. McDonald, J. N. Crawley, K. Sandhoff, K. Suzuki, et al. 1995. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11: 170-176.
170. Andersson, U., D. Smith, M. Jeyakumar, T. D. Butters, M. C. Borja, R. A. Dwek, and F. M. Platt. 2004. Improved outcome of N-butyldeoxygalactonojirimycin- mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 16: 506-515.
171. Baek, R. C., J. L. Kasperzyk, F. M. Platt, and T. N. Seyfried. 2008. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem. Int. 52: 1125-1133.
172. Sakuraba, H., K. Itoh, M. Shimmoto, K. Utsumi, R. Kase, Y. Hashimoto, T. Ozawa, Y. Ohwada, G. Imataka, M. Eguchi, et al. 1999. GM2 gangliosidosis AB variant: clinical and biochemical studies of a Japanese patient. Neurology. 52: 372-377.
173. Schroder, M., D. Schnabel, K. Suzuki, and K. Sandhoff. 1991. A mutation in the gene of a glycolipid-binding protein (GM2 activator) that causes GM2-gangliosidosis variant AB. FEBS Lett. 290: 1-3.
174. Schulze, H., T. Kolter, and K. Sandhoff. 2009. Principles of lysosomal membrane degradation: cellular topology and biochemistry of lysosomal lipid degradation. Biochim. Biophys. Acta. 1793: 674-683.
175. Liu, Y., A. Hoffmann, A. Grinberg, H. Westphal, M. P. McDonald, K. M. Miller, J. N. Crawley, K. Sandhoff, K. Suzuki, and R. L. Proia. 1997. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc. Natl. Acad. Sci. USA. 94: 8138-8143. (Pubitemid 127641485)
176. Elleder, M., M. Jerabkova, A. Befekadu, M. Hrebicek, L. Berna, J. Ledvinova, H. Hulkova, H. Rosewich, N. Schymik, B. C. Paton, et al. 2005. Prosaposin deficiency-a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics. 36: 171-180.
177. Harzer, K., B. C. Paton, A. Poulos, B. Kustermann-Kuhn, W. Roggendorf, T. Grisar, and M. Popp. 1989. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur. J. Pediatr. 149: 31-39. (Pubitemid 19256486)
178. Hulkova, H., M. Cervenkova, J. Ledvinova, M. Tochackova, M. Hrebicek, H. Poupetova, A. Befekadu, L. Berna, B. C. Paton, K. Harzer, et al. 2001. A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Hum. Mol. Genet. 10: 927-940.
179. Ciaffoni, F., M. Tatti, A. Boe, R. Salvioli, A. Fluharty, S. Sonnino, and A. M. Vaccaro. 2006. Saposin B binds and transfers phospholipids. J. Lipid Res. 47: 1045-1053.
180. Ahn, V. E., K. F. Faull, J. P. Whitelegge, A. L. Fluharty, and G. G. Prive. 2003. Crystal structure of saposin B reveals a dimeric shell for lipid binding. Proc. Natl. Acad. Sci. USA. 100: 38-43.
181. Sandhoff, K., T. Kolter, and K. Harzer. 2001. Sphingolipid activator proteins. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3371-3387.
182. Sun, Y., X. Qi, and G. A. Grabowski. 2003. Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J. Biol. Chem. 278: 31918-31923.
183. Alattia, J. R., J. E. Shaw, C. M. Yip, and G. G. Prive. 2007. Molecular imaging of membrane interfaces reveals mode of beta-gluco sidase activation by saposin C. Proc. Natl. Acad. Sci. USA. 104: 17394-17399.
184. Qi, X., and G. A. Grabowski. 1998. Acid beta-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C. Biochemistry. 37: 11544-11554.
185. Soeda, S., M. Hiraiwa, J. S. O'Brien, and Y. Kishimoto. 1993. Binding of cerebrosides and sulfatides to saposins A-D. J. Biol. Chem. 268: 18519-18523. (Pubitemid 23273784)
186. Vaccaro, A. M., M. Tatti, F. Ciaffoni, R. Salvioli, A. Barca, and C. Scerch. 1997. Effect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramide. J. Biol. Chem. 272: 16862-16867.
187. Spiegel, R., G. Bach, V. Sury, G. Mengistu, B. Meidan, S. Shalev, Y. Shneor, H. Mandel, and M. Zeigler. 2005. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. Mol. Genet. Metab. 84: 160-166.
188. Tylki-Szymanska, A., B. Czartoryska, M. T. Vanier, B. J. Poorthuis, J. A. Groener, A. Lugowska, G. Millat, A. M. Vaccaro, and E. Jurkiewicz. 2007. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin. Genet. 72: 538-542.
189. Diaz-Font, A., B. Cormand, R. Santamaria, L. Vilageliu, D. Grinberg, and A. Chabas. 2005. A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebrosidase activity. Hum. Genet. 117: 275-277.
190. Fujita, N., K. Suzuki, M. T. Vanier, B. Popko, N. Maeda, A. Klein, M. Henseler, K. Sandhoff, and H. Nakayasu. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5: 711-725.
191. Matsuda, J., M. T. Vanier, Y. Saito, J. Tohyama, K. Suzuki, and K. Suzuki. 2001. A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum. Mol. Genet. 10: 1191-1199. (Pubitemid 32487542)
192. Sun, Y., X. Qi, D. P. Witte, E. Ponce, K. Kondoh, B. Quinn, and G. A. Grabowski. 2002. Prosaposin: threshold rescue and analysis of the "neuritogenic" region in transgenic mice. Mol. Genet. Metab. 76: 271-286.
193. Sun, Y., H. Ran, M. Zamzow, K. Kitatani, M. R. Skelton, M. T. Williams, C. V. Vorhees, D. P. Witte, Y. A. Hannun, and G. A. Grabowski. 2010. Specific saposin C deficiency: CNS impairment and acid {beta}- glucosidase effects in the mouse. Hum Mol Genet. 19: 634-647.
194. Sun, Y., D. P. Witte, H. Ran, M. Zamzow, S. Barnes, H. Cheng, X. Han, M. T. Williams, M. R. Skelton, C. V. Vorhees, et al. 2008. Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice. Hum. Mol. Genet. 17: 2345-2356.
195. Lloyd-Evans, E., A. J. Morgan, X. He, D. A. Smith, E. Elliot-Smith, D. J. Sillence, G. C. Churchill, E. H. Schuchman, A. Galione, and F. M. Platt. 2008. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14: 1247-1255.
196. Kwon, H. J., L. Abi-Mosleh, M. L. Wang, J. Deisenhofer, J. L. Goldstein, M. S. Brown, and R. E. Infante. 2009. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 137: 1213-1224.
197. Lloyd-Evans, E., and F. M. Platt. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C Disease. Traffic. Epub 2010 Jan 6.
198. Loftus, S. K., J. A. Morris, E. D. Carstea, J. Z. Gu, C. Cummings, A. Brown, J. Ellison, K. Ohno, M. A. Rosenfeld, D. A. Tagle, et al. 1997. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science. 277: 232-235.
199. Infante, R. E., M. L. Wang, A. Radhakrishnan, H. J. Kwon, M. S. Brown, and J. L. Goldstein. 2008. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl. Acad. Sci. USA. 105: 15287-15292.
200. Sleat, D. E., J. A. Wiseman, M. El-Banna, S. M. Price, L. Verot, M. M. Shen, G. S. Tint, M. T. Vanier, S. U. Walkley, and P. Lobel. 2004. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc. Natl. Acad. Sci. USA. 101: 5886-5891.
201. Hess, B., S. Kafert, U. Heinisch, D. A. Wenger, J. Zlotogora, and V. Gieselmann. 1996. Characterization of two arylsulfatase A missense mutations D335V and T274M causing late infantile metachromatic leukodystrophy. Hum. Mutat. 7: 311-317.
202. Pintos-Morell, G., and M. Beck. 2009. Fabry disease in children and the effects of enzyme replacement treatment. Eur. J. Pediatr. 168: 1355-1363.
203. Nilsson, O., G. A. Grabowski, M. D. Ludman, R. J. Desnick, and L. Svennerholm. 1985. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin. Genet. 27: 443-450. (Pubitemid 15009653)
204. Tohyama, J., M. T. Vanier, K. Suzuki, T. Ezoe, and J. Matsuda. 2000. Paradoxical influence of acid beta-galactosidase gene dosage on phenotype of the twitcher mouse (genetic galactosylceramidase deficiency). Hum. Mol. Genet. 9: 1699-1707. (Pubitemid 30427007)
205. Sun, Y., B. Liou, H. Ran, M. R. Skelton, M. T. Williams, C. V. Vorhees, K. Kitatani, Y. A. Hannun, D. P. Witte, Y. H. Xu, et al. 2010. Neuronopathic Gaucher disease in the mouse: Viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 19: 1088-1097.
206. Vanier, M. T. 1999. Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem. Res. 24: 481-489.
207. Frey, L. C., S. P. Ringel, and C. M. Filley. 2005. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch. Neurol. 62: 989-994.
208. Orvisky, E., E. Sidransky, C. E. McKinney, M. E. Lamarca, R. Samimi, D. Krasnewich, B. M. Martin, and E. I. Ginns. 2000. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr. Res. 48: 233-237. (Pubitemid 30497342)
209. Tanaka, K., H. Nagara, T. Kobayashi, and I. Goto. 1988. The twitcher mouse: accumulation of galactosylsphingosine and pathology of the sciatic nerve. Brain Res. 454: 340-346.
210. Tanaka, K., H. Nagara, T. Kobayashi, and I. Goto. 1989. The twitcher mouse: accumulation of galactosylsphingosine and pathology of the central nervous system. Brain Res. 482: 347-350.
211. Wada, R., C. J. Tifft, and R. L. Proia. 2000. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. USA. 97: 10954-10959.
212. Sun, Y., L. Jia, M. T. Williams, M. Zamzow, H. Ran, B. Quinn, B. J. Aronow, C. V. Vorhees, D. P. Witte, and G. A. Grabowski. 2008. Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient mice. BMC Neurosci. 9: 76.
213. Kim, E. Y., Y. B. Hong, S. H. Go, B. Lee, and S. C. Jung. 2006. Downregulation of neurotrophic factors in the brain of a mouse model of Gaucher disease; implications for neuronal loss in Gaucher disease. Exp. Mol. Med. 38: 348-356.
214. Crowley, C., S. D. Spencer, M. C. Nishimura, K. S. Chen, S. Pitts- Meek, M. P. Armanini, L. H. Ling, S. B. McMahon, D. L. Shelton, A. D. Levinson, et al. 1994. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell. 76: 1001-1011.
215. Ernfors, P., K. F. Lee, and R. Jaenisch. 1994. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature. 368: 147-150.
216. Atsumi, S., C. Nosaka, H. Iinuma, and K. Umezawa. 1993. Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch. Biochem. Biophys. 304: 302-304.
217. Leonova, T., and G. A. Grabowski. 2000. Fate and sorting of acid beta-glucosidase in transgenic mammalian cells. Mol. Genet. Metab. 70: 281-294.
218. Taniguchi, M., Y. Shinoda, H. Ninomiya, M. T. Vanier, and K. Ohno. 2001. Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain. Brain Dev. 23: 414-421.
219. Brunngraber, E. G., B. Berra, and V. Zambotti. 1973. Altered levels of tissue glycoproteins, gangliosides, glycosaminoglycans and lipids in Niemann-Pick's disease. Clin. Chim. Acta. 48: 173-181.
220. Walkley, S. U. 2004. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 15: 433-444.
221. Jabs, S., A. Quitsch, R. Kakela, B. Koch, J. Tyynela, H. Brade, M. Glatzel, S. Walkley, P. Saftig, M. T. Vanier, et al. 2008. Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis. J. Neurochem. 106: 1415-1425.
222. Rouser, G., C. Galli, and G. Kritchevsky. 1965. Lipid class composition of normal human brain and variations in metachromatic leucodystrophy, Tay-Sachs, Niemann-Pick, chronic Gaucher's and Alzheimer's diseases. J. Am. Oil Chem. Soc. 42: 404-410.
223. Walkley, S. U. 1998. Cellular pathology of lysosomal storage disorders. Brain Pathol. 8: 175-193.
224. Sandhoff, K., and T. Kolter. 1996. Topology of glycosphingolipid degradation. Trends Cell Biol. 6: 98-103.
225. Goker-Alpan, O., G. Lopez, J. Vithayathil, J. Davis, M. Hallett, and E. Sidransky. 2008. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65: 1353-1357.
226. Latourelle, J. C., N. Pankratz, A. Dumitriu, J. B. Wilk, S. Goldwurm, G. Pezzoli, C. B. Mariani, A. L. DeStefano, C. Halter, J. F. Gusella, et al. 2009. Genomewide association study for onset age in Parkinson disease. BMC Med. Genet. 10: 98.
227. Wong, K., E. Sidransky, A. Verma, T. Mixon, G. D. Sandberg, L. K. Wakefield, A. Morrison, A. Lwin, C. Colegial, J. M. Allman, et al. 2004. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82: 192-207.
228. Jmoudiak, M., and A. H. Futerman. 2005. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129: 178-188.
229. Boot, R. G., M. Verhoek, M. de Fost, C. E. Hollak, M. Maas, B. Bleijlevens, M. J. van Breemen, M. van Meurs, L. A. Boven, J. D. Laman, et al. 2004. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 103: 33-39.
230. Barak, V., M. Acker, B. Nisman, I. Kalickman, A. Abrahamov, A. Zimran, and S. Yatziv. 1999. Cytokines in Gaucher's disease. Eur. Cytokine Netw. 10: 205-210.
231. Boven, L. A., M. van Meurs, R. G. Boot, A. Mehta, L. Boon, J. M. Aerts, and J. D. Laman. 2004. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 122: 359-369.
232. Hollak, C. E., L. Evers, J. M. Aerts, and M. H. van Oers. 1997. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol. Dis. 23: 201-212.
233. Frings, W., J. Dreier, and C. Sorg. 2002. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol esteractivated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 526: 93-96.
234. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
235. Gratchev, A., P. Guillot, N. Hakiy, O. Politz, C. E. Orfanos, K. Schledzewski, and S. Goerdt. 2001. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand. J. Immunol. 53: 386-392.
236. Dhami, R., M. A. Passini, and E. H. Schuchman. 2006. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice. Mol. Ther. 13: 556-564.
237. Pyo, H., E. Joe, S. Jung, S. H. Lee, and I. Jou. 1999. Gangliosides activate cultured rat brain microglia. J. Biol. Chem. 274: 34584-34589. (Pubitemid 129509494)
238. Shen, W., K. Stone, A. Jales, D. Leitenberg, and S. Ladisch. 2008. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J. Immunol. 180: 4425-4432.
239. Jeyakumar, M., R. Thomas, E. Elliot-Smith, D. A. Smith, A. C. van der Spoel, A. d'Azzo, V. H. Perry, T. D. Butters, R. A. Dwek, and F. M. Platt. 2003. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 126: 974-987.
240. Jeyakumar, M., D. A. Smith, I. M. Williams, M. C. Borja, D. C. Neville, T. D. Butters, R. A. Dwek, and F. M. Platt. 2004. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol. 56: 642-649.
241. Wu, Y. P., and R. L. Proia. 2004. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc. Natl. Acad. Sci. USA. 101: 8425-8430.
242. Smith, D., K. L. Wallom, I. M. Williams, M. Jeyakumar, and F. M. Platt. 2009. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis. 36: 242-251.
243. Matsuda, J., M. T. Vanier, Y. Saito, and K. Suzuki. 2001. Dramatic phenotypic improvement during pregnancy in a genetic leukodystrophy: estrogen appears to be a critical factor. Hum. Mol. Genet. 10: 2709-2715. (Pubitemid 33133412)
244. Korhonen, R., H. Kankaanranta, A. Lahti, M. Lahde, R. G. Knowles, and E. Moilanen. 2001. Bi-directional effects of the elevation of intracellular calcium on the expression of inducible nitric oxide synthase in J774 macrophages exposed to low and to high concentrations of endotoxin. Biochem. J. 354: 351-358.
245. Giri, S., M. Khan, N. Nath, I. Singh, and A. K. Singh. 2008. The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem. 105: 1820-1833.
246. Jeon, S. B., H. J. Yoon, S. H. Park, I. H. Kim, and E. J. Park. 2008. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brainresident immune cells. J. Immunol. 181: 8077-8087.
247. Kitatani, K., K. Sheldon, V. Anelli, R. W. Jenkins, Y. Sun, G. A. Grabowski, L. M. Obeid, and Y. A. Hannun. 2009. Acid betaglucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J. Biol. Chem. 284: 12979-12988.
248. Gadola, S. D., J. D. Silk, A. Jeans, P. A. Illarionov, M. Salio, G. S. Besra, R. Dwek, T. D. Butters, F. M. Platt, and V. Cerundolo. 2006. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J. Exp. Med. 203: 2293-2303.
249. Zhou, D., J. Mattner, C. Cantu 3rd, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science. 306: 1786-1789.
250. Porubsky, S., A. O. Speak, B. Luckow, V. Cerundolo, F. M. Platt, and H. J. Grone. 2007. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. USA. 104: 5977-5982.
251. Cox, D., L. Fox, R. Tian, W. Bardet, M. Skaley, D. Mojsilovic, J. Gumperz, and W. Hildebrand. 2009. Determination of cellular lipids bound to human CD1d molecules. PLoS One. 4: e5325.
252. Conradi, N. G., P. Sourander, O. Nilsson, L. Svennerholm, and A. Erikson. 1984. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol. 65: 99-109.
253. Kaye, E. M., M. D. Ullman, E. R. Wilson, and J. A. Barranger. 1986. Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann. Neurol. 20: 223-230. (Pubitemid 16044209)
254. Tessitore, A., M. del P. Martin, R. Sano, Y. Ma, L. Mann, A. Ingrassia, E. D. Laywell, D. A. Steindler, L. M. Hendershot, and A. d'Azzo. 2004. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell. 15: 753-766.
255. Farfel-Becker, T., E. Vitner, H. Dekel, N. Leshem, I. B. Enquist, S. Karlsson, and A. H. Futerman. 2009. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet. 18: 1482-1488.
256. Huang, J. Q., J. M. Trasler, S. Igdoura, J. Michaud, N. Hanal, and R. A. Gravel. 1997. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 6: 1879-1885.
257. Nixon, R. A., D. S. Yang, and J. H. Lee. 2008. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 4: 590-599.
258. Pelled, D., E. Lloyd-Evans, C. Riebeling, M. Jeyakumar, F. M. Platt, and A. H. Futerman. 2003. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem. 278: 29496-29501.
259. d'Azzo, A., A. Tessitore, and R. Sano. 2006. Gangliosides as apo ptotic signals in ER stress response. Cell Death Differ. 13: 404-414.
260. Higashi, Y., S. Murayama, P. G. Pentchev, and K. Suzuki. 1993. Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol. 85: 175-184. (Pubitemid 23068507)
261. Macauley, S. L., R. L. Sidman, E. H. Schuchman, T. Taksir, and G. R. Stewart. 2008. Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration. Exp. Neurol. 214: 181-192.
262. Pampols, T., M. Pineda, M. L. Giros, I. Ferrer, V. Cusi, A. Chabas, F. X. Sanmarti, M. T. Vanier, and H. Christomanou. 1999. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Acta Neuropathol (Berl). 97: 91-97.
263. Mannan, A. U., E. Roussa, C. Kraus, M. Rickmann, J. Maenner, K. Nayernia, K. Krieglstein, A. Reis, and W. Engel. 2004. Mutation in the gene encoding lysosomal acid phosphatase (Acp2) causes cerebellum and skin malformation in mouse. Neurogenetics. 5: 229-238.
264. Rudelius, M., A. Osanger, S. Kohlmann, M. Augustin, G. Piontek, U. Heinzmann, G. Jennen, A. Russ, K. Matiasek, G. Stumm, et al. 2006. A missense mutation in the WD40 domain of murine Lyst is linked to severe progressive Purkinje cell degeneration. Acta Neuropathol. 112: 267-276.
265. Weimer, J. M., J. W. Benedict, A. L. Getty, C. C. Pontikis, M. J. Lim, J. D. Cooper, and D. A. Pearce. 2009. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1266: 93-107.
266. Sun, Y., D. P. Witte, M. Zamzow, H. Ran, B. Quinn, J. Matsuda, and G. A. Grabowski. 2007. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum. Mol. Genet. 16: 957-971.
267. Pacheco, C. D., R. Kunkel, and A. P. Lieberman. 2007. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum. Mol. Genet. 16: 1495-1503.
268. Pacheco, C. D., and A. P. Lieberman. 2008. The pathogenesis of Niemann-Pick type C disease: a role for autophagy? Expert Rev. Mol. Med. 10: e26.
269. Yadid, G., I. Sotnik-Barkai, C. Tornatore, B. Baker-Cairns, J. Harvey-White, P. G. Pentchev, and E. Goldin. 1998. Neurochemical alterations in the cerebellum of a murine model of Niemann-Pick type C disease. Brain Res. 799: 250-256.
270. Coleman, M. 2005. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 6: 889-898.
271. Walkley, S. U., M. Zervas, and S. Wiseman. 2000. Gangliosides as modulators of dendritogenesis in normal and storage diseaseaffected pyramidal neurons. Cereb. Cortex. 10: 1028-1037.
272. Komatsu, M., Q. J. Wang, G. R. Holstein, V. L. Friedrich, Jr., J. Iwata, E. Kominami, B. T. Chait, K. Tanaka, and Z. Yue. 2007. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc. Natl. Acad. Sci. USA. 104: 14489-14494.
273. Walkley, S. U. 2009. Pathogenic cascades in lysosomal disease: Why so complex? J. Inherit. Metab. Dis. 32: 181-189.
274. Sugiura, Y., K. Furukawa, O. Tajima, S. Mii, T. Honda, and K. Furukawa. 2005. Sensory nerve-dominant nerve degeneration and remodeling in the mutant mice lacking complex gangliosides. Neuroscience. 135: 1167-1178.
275. Eckhardt, M., K. K. Hedayati, J. Pitsch, R. Lullmann-Rauch, H. Beck, S. N. Fewou, and V. Gieselmann. 2007. Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy. J. Neurosci. 27: 9009-9021.
276. Zeng, Y., H. Cheng, X. Jiang, and X. Han. 2008. Endosomes and lysosomes play distinct roles in sulfatide-induced neuroblastoma apoptosis: potential mechanisms contributing to abnormal sulfatide metabolism in related neuronal diseases. Biochem. J. 410: 81-92.
277. Miyatake, T., and K. Suzuki. 1972. Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase. Biochem. Biophys. Res. Commun. 48: 539-543.
278. Hannun, Y. A., and R. M. Bell. 1987. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science. 235: 670-674. (Pubitemid 17011106)
279. Hannun, Y. A., and R. M. Bell. 1989. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science. 243: 500-507.
280. Igisu, H., and K. Suzuki. 1984. Glycolipids of the spinal cord, sciatic nerve, and systemic organs of the twitcher mouse. J. Neuropathol. Exp. Neurol. 43: 22-36. (Pubitemid 14187677)
281. Igisu, H., and K. Suzuki. 1984. Progressive accumulation of toxic metabolite in a genetic leukodystrophy. Science. 224: 753-755. (Pubitemid 14140043)
282. Svennerholm, L., M. T. Vanier, and J. E. Mansson. 1980. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J. Lipid Res. 21: 53-64. (Pubitemid 10120438)
283. White, A. B., M. I. Givogri, A. Lopez-Rosas, H. Cao, R. van Breemen, G. Thinakaran, and E. R. Bongarzone. 2009. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J. Neurosci. 29: 6068-6077.
284. Schueler, U. H., T. Kolter, C. R. Kaneski, J. K. Blusztajn, M. Herkenham, K. Sandhoff, and R. O. Brady. 2003. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol. Dis. 14: 595-601.
285. Lloyd-Evans, E., D. Pelled, C. Riebeling, J. Bodennec, A. de-Morgan, H. Waller, R. Schiffmann, and A. H. Futerman. 2003. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 278: 23594-23599.
286. Kacher, Y., and A. H. Futerman. 2006. Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options. FEBS Lett. 580: 5510-5517.
287. D'Hooge, R., R. Lullmann-Rauch, T. Beckers, D. Balschun, M. Schwake, K. Reiss, K. von Figura, and P. Saftig. 2005. Neurocognitive and psychotiform behavioral alterations and enhanced hippocampal long-term potentiation in transgenic mice displaying neuropathological features of human alpha-mannosidosis. J. Neurosci. 25: 6539-6549.
288. Malenka, R. C., and R. A. Nicoll. 1999. Long-term potentiation-a decade of progress? Science. 285: 1870-1874.
289. Foster, T. C., and A. Kumar. 2002. Calcium dysregulation in the aging brain. Neuroscientist. 8: 297-301.
290. Lloyd-Evans, E., D. Pelled, C. Riebeling, and A. H. Futerman. 2003. Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochem. J. 375: 561-565.
291. Ginzburg, L., and A. H. Futerman. 2005. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J. Neurochem. 95: 1619-1628.
292. Bramham, C. R., and E. Messaoudi. 2005. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog. Neurobiol. 76: 99-125.
293. Nolan, Y., D. Martin, V. A. Campbell, and M. A. Lynch. 2004. Evidence of a protective effect of phosphatidylserine-containing liposomes on lipopolysaccharide-induced impairment of long-term potentiation in the rat hippocampus. J. Neuroimmunol. 151: 12-23.
294. Henderson, L. P., L. Lin, A. Prasad, C. A. Paul, T. Y. Chang, and R. A. Maue. 2000. Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness. J. Biol. Chem. 275: 20179-20187.
295. Schiffmann, R. 2009. Fabry disease. Pharmacol. Ther. 122: 65-77.
296. Grubb, J. H., C. Vogler, B. Levy, N. Galvin, Y. Tan, and W. S. Sly. 2008. Chemically modified beta-glucuronidase crosses bloodbrain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA. 105: 2616-2621.
297. Montano, A. M., H. Oikawa, S. Tomatsu, T. Nishioka, C. Vogler, M. A. Gutierrez, T. Oguma, Y. Tan, J. H. Grubb, V. C. Dung, et al. 2008. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol. Genet. Metab. 94: 178-189.
298. Chen, Y. H., M. Chang, and B. L. Davidson. 2009. Molecular signatures of disease brain endothelia provide new sites for CNSdirected enzyme therapy. Nat. Med. 15: 1215-1218.
299. Wang, D., W. Zhang, T. A. Kalfa, G. Grabowski, S. Davies, P. Malik, and D. Pan. 2009. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc. Natl. Acad. Sci. USA. 106: 19958-19963.
300. Biffi, A., A. Capotondo, S. Fasano, U. del Carro, S. Marchesini, H. Azuma, M. C. Malaguti, S. Amadio, R. Brambilla, M. Grompe, et al. 2006. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 116: 3070-3082.
301. Galbiati, F., M. I. Givogri, L. Cantuti, A. L. Rosas, H. Cao, R. van Breemen, and E. R. Bongarzone. 2009. Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. J. Neurosci. Res. 87: 1748-1759.
302. Klein, D., T. Schmandt, E. Muth-Kohne, A. Perez-Bouza, M. Segschneider, V. Gieselmann, and O. Brustle. 2006. Embryonic stem cell-based reduction of central nervous system sulfatide storage in an animal model of metachromatic leukodystrophy. Gene Ther. 13: 1686-1695.
303. Papadeas, S. T., and N. J. Maragakis. 2009. Advances in stem cell research for amyotrophic lateral sclerosis. Curr Opin Biotechnol. 20: 545-51.
304. Weinreb, N. J., J. A. Barranger, J. Charrow, G. A. Grabowski, H. J. Mankin, and P. Mistry. 2005. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am. J. Hematol. 80: 223-229.
305. Wraith, J. E., and J. Imrie. 2009. New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 5: 877-887.
306. Galanaud, D., A. Tourbah, S. Lehericy, N. Leveque, B. Heron, T. Billette de Villemeur, N. Guffon, F. Feillet, N. Baumann, M. T. Vanier, et al. 2009. 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol. Genet. Metab. 96: 55-58.
307. McEachern, K. A., J. Fung, S. Komarnitsky, C. S. Siegel, W. L. Chuang, E. Hutto, J. A. Shayman, G. A. Grabowski, J. M. Aerts, S. H. Cheng, et al. 2007. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91: 259-267.
308. Peterschmitt, J., E. Lukina, N. Watman, E. A. Arreguin, M. Banikazemi, G. Pastores, M. Lastrebner, M. Dragosky, H. Rosenbaum, M. Phillips, et al. 2009. Genz-112638 for Gaucher disease type 1: Phase 2 clinical trial results after one year of treatment. In 59th Annual Meeting on The American Society of Human Genetics, Honolulu, Hawaii. Available at http://www.ashg. org/2009meeting/ abstracts/fulltext.
309. Benjamin, E. R., J. J. Flanagan, A. Schilling, H. H. Chang, L. Agarwal, E. Katz, X. Wu, C. Pine, B. Wustman, R. J. Desnick, et al. 2009. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J. Inherit. Metab. Dis. 32: 424-440.
310. Steet, R. A., S. Chung, B. Wustman, A. Powe, H. Do, and S. A. Kornfeld. 2006. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl. Acad. Sci. USA. 103: 13813-13818.
311. Yu, Z., A. R. Sawkar, L. J. Whalen, C. H. Wong, and J. W. Kelly. 2007. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J. Med. Chem. 50: 94-100.
312. Davidson, C. D., N. F. Ali, M. C. Micsenyi, G. Stephney, S. Renault, K. Dobrenis, D. S. Ory, M. T. Vanier, and S. U. Walkley. 2009. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 4: e6951.
313. Galonic, D. P., and D. Y. Gin. 2007. Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. Nature. 446: 1000-1007.
314. Furukawa, K., N. Tokuda, T. Okuda, and O. Tajima. 2004. Glycosphingolipids in engineered mice: insights into function. Semin. Cell Dev. Biol. 15: 389-396.
315. Sabourdy, F., B. Kedjouar, S. C. Sorli, S. Colie, D. Milhas, Y. Salma, and T. Levade. 2008. Functions of sphingolipid metabolism in mammals-lessons from genetic defects. Biochim. Biophys. Acta. 1781: 145-183.
316. Jeckel, D., A. Karrenbauer, K. N. Burger, G. van Meer, and F. Wieland. 1992. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J. Cell Biol. 117: 259-267.
317. van Meer, G., J. Wolthoorn, and S. Degroote. 2003. The fate and function of glycosphingolipid glucosylceramide. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358: 869-873.
318. Kolter, T., R. L. Proia, and K. Sandhoff. 2002. Combinatorial ganglioside biosynthesis. J. Biol. Chem. 277: 25859-25862.
319. Fukasawa, M., M. Nishijima, and K. Hanada. 1999. Genetic evidence for ATP-dependent endoplasmic reticulum-to-Golgi apparatus trafficking of ceramide for sphingomyelin synthesis in Chinese hamster ovary cells. J. Cell Biol. 144: 673-685.
320. Hogan, B., R. Beddington, F. Costantini, and E. Lacy, editors. 1994. Manipulatiing the mouse embryo: a laboraory manual. Second edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
321. Koch, J., S. Gartner, C. M. Li, L. E. Quintern, K. Bernardo, O. Levran, D. Schnabel, R. J. Desnick, E. H. Schuchman, and K. Sandhoff. 1996. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease. J. Biol. Chem. 271: 33110-33115.
322. Li, C. M., S. B. Hong, G. Kopal, X. He, T. Linke, W. S. Hou, J. Koch, S. Gatt, K. Sandhoff, and E. H. Schuchman. 1998. Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics. 50: 267-274.
323. Park, J. H., and E. H. Schuchman. 2006. Acid ceramidase and human disease. Biochim. Biophys. Acta. 1758: 2133-2138.
324. Simonaro, C. M., J. H. Park, E. Eliyahu, N. Shtraizent, M. M. McGovern, and E. H. Schuchman. 2006. Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. Am. J. Hum. Genet. 78: 865-870.
325. Sogawa, H., K. Horino, F. Nakamura, T. Kudoh, K. Oyanagi, T. Yamanouchi, R. Minami, T. Nakao, A. Watanabe, and Y. Matsuura. 1978. Chronic Niemann-Pick disease with sphingomyelinase deficiency in two brothers with mental retardation. Eur. J. Pediatr. 128: 235-240. (Pubitemid 8354039)
326. Patterson, M. C., M. T. Vanier, K. Suzuki, J. M. Morris, E. Carstea, E. B. Neufeld, J. E. Blanchette-Mackie, and P. G. Pentchev. 2001. Niemann-Pick Disease Type C: A Lipid Trafficking Disorder. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw- Hill, New York. 3611-3633.
327. Tang, Y., H. Li, and J. P. Liu. 2010. Niemann-Pick Disease Type C: from molecule to clinic. Clin. Exp. Pharmacol. Physiol. 37: 132-140.
328. Vanier, M. T., and G. Millat. 2003. Niemann-Pick disease type C. Clin. Genet. 64: 269-281.
329. Millat, G., K. Chikh, S. Naureckiene, D. E. Sleat, A. H. Fensom, K. Higaki, M. Elleder, P. Lobel, and M. T. Vanier. 2001. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. J. Hum. Genet. 69: 1013-1021.
330. Naureckiene, S., D. E. Sleat, H. Lackland, A. Fensom, M. T. Vanier, R. Wattiaux, M. Jadot, and P. Lobel. 2000. Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 290: 2298-2301.
331. Miyawaki, S., S. Mitsuoka, T. Sakiyama, and T. Kitagawa. 1982. Sphingomyelinosis, a new mutation in the mouse: a model of Niemann-Pick disease in humans. J. Hered. 73: 257-263. (Pubitemid 12053273)
332. Pentchev, P. G., A. D. Boothe, H. S. Kruth, H. Weintroub, J. Stivers, and R. O. Brady. 1984. A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem. 259: 5784-5791.
333. Reid, P. C., N. Sakashita, S. Sugii, Y. Ohno-Iwashita, Y. Shimada, W. F. Hickey, and T. Y. Chang. 2004. A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann- Pick type C1 mouse brain. J. Lipid Res. 45: 582-591.
334. Treiber-Held, S., R. Distl, V. Meske, F. Albert, and T. G. Ohm. 2003. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. J. Pathol. 200: 95-103.
335. Lissens, W., A. Arena, S. Seneca, M. Rafi, G. Sorge, I. Liebaers, D. Wenger, and A. Fiumara. 2007. A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. Hum. Mutat. 28: 742.
336. Xu, C., N. Sakai, M. Taniike, K. Inui, and K. Ozono. 2006. Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation. J. Hum. Genet. 51: 548-554.
337. De Gasperi, R., M. A. Gama Sosa, E. L. Sartorato, S. Battistini, H. MacFarlane, J. F. Gusella, W. Krivit, and E. H. Kolodny. 1996. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. Am. J. Hum. Genet. 59: 1233-1242. (Pubitemid 26394114)
338. Furuya, H., Y. Kukita, S. Nagano, Y. Sakai, Y. Yamashita, H. Fukuyama, Y. Inatomi, Y. Saito, R. Koike, S. Tsuji, et al. 1997. Adult onset globoid cell leukodystrophy (Krabbe disease): analysis of galactosylceramidase cDNA from four Japanese patients. Hum. Genet. 100: 450-456.
339. Duchen, L. W., E. M. Eicher, J. M. Jacobs, F. Scaravilli, and F. Teixeira. 1980. Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain. 103: 695-710. (Pubitemid 10001187)
340. Mohri, I., M. Taniike, H. Taniguchi, T. Kanekiyo, K. Aritake, T. Inui, N. Fukumoto, N. Eguchi, A. Kushi, H. Sasai, et al. 2006. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J. Neurosci. 26: 4383-4393.
341. Phelan, M. C., G. R. Thomas, R. A. Saul, R. C. Rogers, H. A. Taylor, D. A. Wenger, and H. E. McDermid. 1992. Cytogenetic, biochemical, and molecular analyses of a 22q13 deletion. Am. J. Med. Genet. 43: 872-876.
342. Gieselmann, V., A. Polten, J. Kreysing, and K. von Figura. 1989. Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site. Proc. Natl. Acad. Sci. USA. 86: 9436-9440.
343. Hoffmann, B. 2009. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J. Rare Dis. 4: 21.
344. Desnick, R. J., K. H. Astrin, and D. F. Bishop. 1989. Fabry disease: molecular genetics of the inherited nephropathy. Adv. Nephrol. Necker Hosp. 18: 113-127.
345. Grzeschik, K. H., A. M. Grzeschik, S. Banhof, G. Romeo, M. Siniscalco, H. van Someren, P. Meera Khan, A. Westerveld, and D. Bootsma. 1972. X-linkage of human -galactosidase. Nat. New Biol. 240: 48-50.
346. Ramaswami, U., C. Whybra, R. Parini, G. Pintos-Morell, A. Mehta, G. Sunder-Plassmann, U. Widmer, and M. Beck. 2006. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 95: 86-92.
347. Meikle, P. J., J. J. Hopwood, A. E. Clague, and W. F. Carey. 1999. Prevalence of lysosomal storage disorders. JAMA. 281: 249-254.
348. Shabbeer, J., M. Yasuda, S. D. Benson, and R. J. Desnick. 2006. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum. Genomics. 2: 297-309.
349. Ohshima, T., G. J. Murray, W. D. Swaim, G. Longenecker, J. M. Quirk, C. O. Cardarelli, Y. Sugimoto, I. Pastan, M. M. Gottesman, R. O. Brady, et al. 1997. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA. 94: 2540-2544.
350. Xu, Y. H., B. Quinn, D. Witte, and G. A. Grabowski. 2003. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 163: 2093-2101.
351. Sinclair, G. B., G. Jevon, K. E. Colobong, D. R. Randall, F. Y. Choy, and L. A. Clarke. 2007. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease. Mol. Genet. Metab. 90: 148-156.
352. Enquist, I. B., E. Nilsson, A. Ooka, J. E. Mansson, K. Olsson, M. Ehinger, R. O. Brady, J. Richter, and S. Karlsson. 2006. Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl. Acad. Sci. USA. 103: 13819-13824.
353. Dreborg, S., A. Erikson, and B. Hagberg. 1980. Gaucher disease-Norrbottnian type. I. General clinical description. Eur. J. Pediatr. 133: 107-118. (Pubitemid 10129468)
354. Amsallem, D., D. Rodriguez, M. Vanier, and E. al. 2005. Third case of Gaucher disease with sap -C deficiency and evaluation of twelve months' therapy by miglustat. J. Inherit. Metab. Dis. 28: 152.
355. Christomanou, H., A. Chabas, T. Pampols, and A. Guardiola. 1989. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Klin. Wochenschr. 67: 999-1003. (Pubitemid 19239576)
356. Rafi, M. A., G. de Gala, X. L. Zhang, and D. A. Wenger. 1993. Mutational analysis in a patient with a variant form of Gaucher disease caused by SAP-2 deficiency. Somat. Cell Mol. Genet. 19: 1-7.
357. Sun, Y., B. Quinn, D. P. Witte, and G. A. Grabowski. 2005. Gaucher disease mouse models: point mutations at the acid {beta}-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 46: 2102-2113.
358. Brunetti-Pierri, N., and F. Scaglia. 2008. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol. Genet. Metab. 94: 391-396.
359. Takano, T., and Y. Yamanouchi. 1993. Assignment of human beta-galactosidase-A gene to 3p21.33 by fluorescence in situ hybridization. Hum. Genet. 92: 403-404.
360. Matsuda, J., O. Suzuki, A. Oshima, A. Ogura, Y. Noguchi, Y. Yamamoto, T. Asano, K. Takimoto, K. Sukegawa, Y. Suzuki, et al. 1997. Beta-galactosidase- deficient mouse as an animal model for GM1-gangliosidosis. Glycoconj. J. 14: 729-736.
361. Yamanaka, S., M. D. Johnson, A. Grinberg, H. Westphal, J. N. Crawley, M. Taniike, K. Suzuki, and R. L. Proia. 1994. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl. Acad. Sci. USA. 91: 9975-9979.
362. Taniike, M., S. Yamanaka, R. L. Proia, C. Langaman, T. Bone-Turrentine, and K. Suzuki. 1995. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol. 89: 296-304.
363. Zampieri, S., M. Filocamo, E. Buratti, M. Stroppiano, K. Vlahovicek, N. Rosso, E. Bignulin, S. Regis, F. Carnevale, B. Bembi, et al. 2009. Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: identification of six novel alleles. Neurogenetics. 10: 49-58.
364. Chen, B., B. Rigat, C. Curry, and D. J. Mahuran. 1999. Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2. Am. J. Hum. Genet. 65: 77-87.
365. Sandhoff, R., R. Geyer, R. Jennemann, C. Paret, E. Kiss, T. Yamashita, K. Gorgas, T. P. Sijmonsma, M. Iwamori, C. Finaz, et al. 2005. Novel class of glycosphingolipids involved in male fertility. J. Biol. Chem. 280: 27310-27318.
366. Sheikh, K. A., J. Sun, Y. Liu, H. Kawai, T. O. Crawford, R. L. Proia, J. W. Griffin, and R. L. Schnaar. 1999. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl. Acad. Sci. USA. 96: 7532-7537.
367. Kawai, H., M. L. Allende, R. Wada, M. Kono, K. Sango, C. Deng, T. Miyakawa, J. N. Crawley, N. Werth, U. Bierfreund, et al. 2001. Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J. Biol. Chem. 276: 6885-6888.
368. Yamashita, T., Y. P. Wu, R. Sandhoff, N. Werth, H. Mizukami, J. M. Ellis, J. L. Dupree, R. Geyer, K. Sandhoff, and R. L. Proia. 2005. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. USA. 102: 2725-2730.
369. Jennemann, R., R. Sandhoff, L. Langbein, S. Kaden, U. Rothermel, H. Gallala, K. Sandhoff, H. Wiegandt, and H. J. Grone. 2007. Integrity and barrier function of the epidermis critically depend on glucosylceramide synthesis. J. Biol. Chem. 282: 3083-3094.
370. Pastores, G. M., D. Elstein, M. Hrebicek, and A. Zimran. 2007. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin. Ther. 29: 1645-1654.
371. Lidove, O., D. Joly, F. Barbey, S. Bekri, J. F. Alexandra, V. Peigne, R. Jaussaud, and T. Papo. 2007. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int. J. Clin. Pract. 61: 293-302.
372. Aerts, J. M., C. E. Hollak, R. G. Boot, J. E. Groener, and M. Maas. 2006. Substrate reduction therapy of glycosphingolipid storage disorders. J. Inherit. Metab. Dis. 29: 449-456.
373. Wortmann, S. B., D. J. Lefeber, G. Dekomien, M. A. Willemsen, R. A. Wevers, and E. Morava. Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis. Epub 2009 Nov 4.
374. Ziegler, R. J., C. Brown, C. M. Barbon, A. M. D'Angona, E. H. Schuchman, L. Andrews, B. L. Thurberg, J. M. McPherson, K. P. Karey, and S. H. Cheng. 2009. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease. Mol. Genet. Metab. 97: 35-42.
375. Pineda, M., J. E. Wraith, E. Mengel, F. Sedel, W. L. Hwu, M. Rohrbach, B. Bembi, M. Walterfang, G. C. Korenke, T. Marquardt, et al. 2009. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab. 98: 243-249.
376. Escolar, M. L., M. D. Poe, J. M. Provenzale, K. C. Richards, J. Allison, S. Wood, D. A. Wenger, D. Pietryga, D. Wall, M. Champagne, et al. 2005. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 352: 2069-2081.
377. Strazza, M., A. Luddi, M. Carbone, M. A. Rafi, E. Costantino-Ceccarini, and D. A. Wenger. 2009. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol. Genet. Metab. 97: 27-34.
378. Matzner, U., E. Herbst, K. K. Hedayati, R. Lullmann-Rauch, C. Wessig, S. Schroder, C. Eistrup, C. Moller, J. Fogh, and V. Gieselmann. 2005. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet. 14: 1139-1152.